Scientist
Janssen
Spring House
Megan Schnarr joined Janssen in 2005 in the Bioassay Method Development Group. In this role, she performed cell-based bioassays and immunoassays for GLP and GMP release and stability materials. In 2012, she joined the Neutralizing Antibody (NAb) Method Development and Validation group in the department of Bioanalytical Discovery and Development Sciences. In this position, she gained experience and knowledge in developing and validating bioanalytical methods to enable NAb assessment to support diverse drug development programs in Janssen. She is responsible for investigating and developing novel methods with a variety of technology platforms for the measurement of NAb to assess immunogenicity to biotherapeutics.
Megan earned a B.A. and M.S degree in Biology from Rutgers University, Camden, NJ.
Bead-Based NAb Assay with High Drug Tolerance for A Bispecific
Monday, October 23, 2023
3:15 PM – 3:30 PM ET